ASXL1 and myeloproliferative neoplasm: To determine whether the decreased ASXL1 expression is a direct cause of the functional alteration of the patient BMSCs, we next introduced WT ASXL1 into BMSCs derived from myeloproliferative neoplasms (MPN) patients.